Your browser doesn't support javascript.
loading
Incidence and prevalence of chronic pulmonary aspergillosis in patients with post-tuberculosis lung abnormality: Results from a community survey in North India.
Soundappan, Kathirvel; Sehgal, Inderpaul Singh; Prabhakar, Nidhi; Rana, Samriti; Raju, Rajesh; Dhooria, Sahajal; Prasad, Kuruswamy Thurai; Muthu, Valliappan; Rudramurthy, Shivaprakash M; Chakrabarti, Arunaloke; Garg, Mandeep; Agarwal, Ritesh.
Afiliação
  • Soundappan K; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Sehgal IS; Department of Pulmonary Medicine, PGIMER, Chandigarh, India.
  • Prabhakar N; Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Rana S; Department of Pulmonary Medicine, PGIMER, Chandigarh, India.
  • Raju R; Civil Hospital, Panchkula, Haryana, India.
  • Dhooria S; Department of Pulmonary Medicine, PGIMER, Chandigarh, India.
  • Prasad KT; Department of Pulmonary Medicine, PGIMER, Chandigarh, India.
  • Muthu V; Department of Pulmonary Medicine, PGIMER, Chandigarh, India.
  • Rudramurthy SM; Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Chakrabarti A; Doodhadhari Burfani Hospital, Haridwar, Uttarakhand, India.
  • Garg M; Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Agarwal R; Department of Pulmonary Medicine, PGIMER, Chandigarh, India.
Mycoses ; 67(3): e13711, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38414309
ABSTRACT

BACKGROUND:

Post-tuberculosis lung abnormality (PTLA) is the most common risk factor for developing chronic pulmonary aspergillosis (CPA). However, the prevalence and incidence of CPA in PTLA patients in India remain unknown.

OBJECTIVES:

We aimed to ascertain the incidence and prevalence of CPA in subjects with PTLA.

METHODS:

We identified a cohort of pulmonary tuberculosis who completed anti-tuberculosis therapy (ATT) before November 2019 from the records of the 12 tuberculosis treatment centers attached to the national program. We recorded the clinical and demographic details. We performed computed tomography (CT) of the chest and estimated serum A. fumigatus-specific IgG. We categorised subjects as PTLA with or without CPA using a composite of clinical, radiological, and microbiological features. We resurveyed the subjects at 6 months (or earlier) for the presence of new symptoms. We calculated the prevalence and the incidence rate (per 100-person years) of CPA.

RESULTS:

We included 117 subjects with PTLA, with a median of 3 years after ATT completion. Eleven subjects had CPA in the initial survey, and one additional case developed CPA during the second survey. The prevalence of CPA in PTLA subjects was 10.3% (12/117). The total observation period was 286.7 person-years. The median (interquartile range) time to develop CPA after ATT completion was 12.5 (5-36.7) months. We found the CPA incidence rate (95% confidence interval) of 4.2 (1.8-6.5) per 100-person years.

CONCLUSION:

Chronic pulmonary aspergillosis complicates 10% of PTLA subjects after successful outcomes with ATT. Four new CPA cases may develop per 100-persons years of observation after ATT completion. We suggest screening patients with PTLA who develop new symptoms for CPA.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose Pulmonar / Aspergilose Pulmonar / Pneumopatias Limite: Humans Idioma: En Revista: Mycoses Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose Pulmonar / Aspergilose Pulmonar / Pneumopatias Limite: Humans Idioma: En Revista: Mycoses Ano de publicação: 2024 Tipo de documento: Article